PRLD
Prelude Therapeutics IncorporatedstockNASDAQ
prelude therapeutics incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. it is developing prt543 that is in phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and prt811, which is in phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. the company is also developing prt1419, a potent and selective inhibitor of the anti-apoptotic protein; prt2527, a potent inhibitor of cdk9 that exhibits high kinome selectivity; prt-sca2 for multiple genomically selected cancers; and prt-k4 for solid tumors. prelude therapeutics incorporated was founded in 2016 and is based in wilmington, delaware.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 3.52 | 2026-11-12 | -8.38% | 0.035 |
| 1M | 3.39 | 2026-10-19 | -4.87% | 2.730 |
| 3M | 5.78 | 2026-08-19 | -44.20% | 2.105 |
| 6M | 4.27 | 2026-05-19 | -24.47% | 1.669 |
| 1Y | 1.67 | 2025-11-19 | +93.11% | 1.743 |
| 2Y | 0.96 | 2024-11-19 | +235.90% | — |
| 5Y | 14.46 | 2021-11-19 | -77.70% | 1.571 |
Prelude Therapeutics Incorporated (NASDAQ:PRLD) stock price today is $3.23, and today's volume is 144,571. PRLD is down 2.273% today. The 30 day average volume is 369,190. PRLD market cap is $258.08M with 80.03M shares outstanding.